Topping Estimates, Teva Reports $5.1 Billion Q3 Revenue

A day after CEO steps down, company reports 2% increase in sales, with U.S. generics revenues up 6%.

Yoram Gabison
Reuters
Yoram Gabison
Reuters

Comments